2324948-66-3
2324948-66-3
Chemical Structure
A3373
- CAS No.: 2324948-66-3
- Formula:C17H9F7N2O
- Molecular Weight:390.25
InChIKey: PJRXCSGWZDFONX-UHFFFAOYSA-N
SMILES: O=C(NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1)C2=CC3=C(N2)C=CC(F)=C3
Biological Activity: A3373, a novel chemical inhibitor of Phospholipase D1 (PLD1) and PLD2, with IC50 of 325 nM and 15.15?μM, respectively, inhibits LPS-induced immune response and plays important roles in autoimmune arthritis, bone demineralization and osteoclastogenesis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
A3373 | 99.57% | A3373, a novel chemical inhibitor of Phospholipase D1 (PLD1) and PLD2, with IC50 of 325 nM and 15.15?μM, respectively, inhibits LPS-induced immune response and plays important roles in autoimmune arthritis, bone demineralization and osteoclastogenesis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Won Chan Hwang, et al. Inhibition of phospholipase D1 induces immunogenic cell death and potentiates cancer immunotherapy in colorectal cancer.Exp Mol Med. 2022 Sep;54(9):1563-1576. [Content Brief]
- [2]. Jin-Sil Park, et al. A newly developed PLD1 inhibitor ameliorates rheumatoid arthritis by regulating pathogenic T and B cells and inhibiting osteoclast differentiation. Immunol Lett. 2023 Sep 16:263:87-96. [Content Brief]
